We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in Store for Becton, Dickinson's (BDX) Q4 Earnings?
Read MoreHide Full Article
Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, is scheduled to release fourth-quarter fiscal 2020 results on Nov 5, before the opening bell.
BD delivered an earnings surprise of 7.3% in the last reported quarter. It beat estimates in each of the trailing four quarters, the average surprise being 5.1%.
Q4 Estimates
For the quarter to be reported, the Zacks Consensus Estimate for adjusted earnings per share (EPS) is pegged at $2.50, suggesting a decline of 24.5% from the prior-year quarter. The same for revenues stands at 4.48 billion, indicating a decrease of 2.2% from the year-ago reported figure.
BD Life Sciences: A Key Catalyst
BD Life Sciences’ fiscal fourth-quarter performance is likely to reflect strong year-over-year growth in revenues from assays, which are used to detect a broad range of infectious diseases, healthcare-associated infections and cancer.
Notably, strong performance by the Diagnostic Systems and Biosciences sub-units may have contributed to the to-be-reported quarter’s performance. In fact, the Zacks Consensus Estimate for fiscal fourth-quarter revenues for this segment is pegged at $1.23 billion, suggesting growth of 8.6% from the year-ago reported figure.
Becton, Dickinson and Company Price and EPS Surprise
In July, BD received the Emergency Use Authorization (EUA) from the FDA for a rapid, point-of-care, SARS-CoV-2 diagnostic test for use with its widely available BD Veritor Plus System, which marked the company’s third diagnostic test to receive EUA for the detection of COVID-19. Also, in the same month, BD launched BD PurPrep patient preoperative skin preparation with sterile solution — the first and only fully sterile povidone-iodine plus isopropyl alcohol single-use antiseptic skin preparation commercially available in the United States.
These developments might get reflected in the fiscal fourth-quarter results.
Further, during the fiscal second quarter, BD closed the acquisition of NAT Diagnostics, an early-stage company with a very innovative platform in the fast-growing molecular point-of-care market. This buyout will strengthen the company’s presence in the molecular point-of-care testing market. This acquisition may have favored the fiscal fourth-quarter performance.
Other Factors to Note
Weak performance by the BD Interventional arm might get reflected in the company’s fiscal fourth-quarter results owing to sluggish performance across Surgery and Peripheral Intervention units.
Nonetheless, robust product pipeline is likely to have contributed to the fiscal fourth-quarter performance.
However, the company anticipates fiscal fourth-quarter results to reflect the impact of foreign exchange headwinds.
Also, the company is likely to have witnessed fall in revenues at its BD Medical segment in the to-be-reported quarter primarily due to weakness in Medication Delivery Solutions unit.
Nonetheless, the company is likely to see revenue growth in Medication Management Solutions unit on the back of solid demand for infusion pumps in the United States under medical necessity and strong growth outside the United States, particularly in Europe.
What the Zacks Model Unveils
Per our proven model, a combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here as you will see below.
Earnings ESP: BD has an Earnings ESP of +1.07%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company carries a Zacks Rank #4 (Sell).
Stocks Worth a Look
Here are some medical stocks worth considering as these have the right combination of elements to post an earnings beat this quarter.
Canopy Growth Corporation (CGC - Free Report) has an Earnings ESP of +7.55% and a Zacks Rank of 3.
Orthofix Medical Inc. (OFIX - Free Report) has an Earnings ESP of +42.86% and a Zacks Rank of 3.
Legal Marijuana: An Investor’s Dream
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.
Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Image: Bigstock
What's in Store for Becton, Dickinson's (BDX) Q4 Earnings?
Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, is scheduled to release fourth-quarter fiscal 2020 results on Nov 5, before the opening bell.
BD delivered an earnings surprise of 7.3% in the last reported quarter. It beat estimates in each of the trailing four quarters, the average surprise being 5.1%.
Q4 Estimates
For the quarter to be reported, the Zacks Consensus Estimate for adjusted earnings per share (EPS) is pegged at $2.50, suggesting a decline of 24.5% from the prior-year quarter. The same for revenues stands at 4.48 billion, indicating a decrease of 2.2% from the year-ago reported figure.
BD Life Sciences: A Key Catalyst
BD Life Sciences’ fiscal fourth-quarter performance is likely to reflect strong year-over-year growth in revenues from assays, which are used to detect a broad range of infectious diseases, healthcare-associated infections and cancer.
Notably, strong performance by the Diagnostic Systems and Biosciences sub-units may have contributed to the to-be-reported quarter’s performance.
In fact, the Zacks Consensus Estimate for fiscal fourth-quarter revenues for this segment is pegged at $1.23 billion, suggesting growth of 8.6% from the year-ago reported figure.
Becton, Dickinson and Company Price and EPS Surprise
Becton, Dickinson and Company price-eps-surprise | Becton, Dickinson and Company Quote
In July, BD received the Emergency Use Authorization (EUA) from the FDA for a rapid, point-of-care, SARS-CoV-2 diagnostic test for use with its widely available BD Veritor Plus System, which marked the company’s third diagnostic test to receive EUA for the detection of COVID-19. Also, in the same month, BD launched BD PurPrep patient preoperative skin preparation with sterile solution — the first and only fully sterile povidone-iodine plus isopropyl alcohol single-use antiseptic skin preparation commercially available in the United States.
These developments might get reflected in the fiscal fourth-quarter results.
Further, during the fiscal second quarter, BD closed the acquisition of NAT Diagnostics, an early-stage company with a very innovative platform in the fast-growing molecular point-of-care market. This buyout will strengthen the company’s presence in the molecular point-of-care testing market. This acquisition may have favored the fiscal fourth-quarter performance.
Other Factors to Note
Weak performance by the BD Interventional arm might get reflected in the company’s fiscal fourth-quarter results owing to sluggish performance across Surgery and Peripheral Intervention units.
Nonetheless, robust product pipeline is likely to have contributed to the fiscal fourth-quarter performance.
However, the company anticipates fiscal fourth-quarter results to reflect the impact of foreign exchange headwinds.
Also, the company is likely to have witnessed fall in revenues at its BD Medical segment in the to-be-reported quarter primarily due to weakness in Medication Delivery Solutions unit.
Nonetheless, the company is likely to see revenue growth in Medication Management Solutions unit on the back of solid demand for infusion pumps in the United States under medical necessity and strong growth outside the United States, particularly in Europe.
What the Zacks Model Unveils
Per our proven model, a combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here as you will see below.
Earnings ESP: BD has an Earnings ESP of +1.07%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company carries a Zacks Rank #4 (Sell).
Stocks Worth a Look
Here are some medical stocks worth considering as these have the right combination of elements to post an earnings beat this quarter.
Zimmer Biomet Holdings, Inc. (ZBH - Free Report) has an Earnings ESP of +4.10% and a Zacks Rank of 3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Canopy Growth Corporation (CGC - Free Report) has an Earnings ESP of +7.55% and a Zacks Rank of 3.
Orthofix Medical Inc. (OFIX - Free Report) has an Earnings ESP of +42.86% and a Zacks Rank of 3.
Legal Marijuana: An Investor’s Dream
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.
Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Download Marijuana Moneymakers FREE >>